Researchers Explain How Prostate Cancer Can Survive Androgen Blockade

A research from Sylvester Comprehensive Cancer Center and the University of Miami Miller School of Medicine shows that prostate cancer cells can synthesize androgens through an alternative pathway that does not rely on CYP17A1, the enzyme at the core of virtually all modern androgen deprivation strategies. Instead of flowing through the classical cholesterol → pregnenolone → DHEA route, tumors can start from a cholesterol‑derived oxysterol and use the enzyme CYP51A1, traditionally viewed as a “cholesterol enzyme,” not a steroidogenic one, to generate DHEA. Once DHEA is available, the usual downstream machinery converts it into testosterone and dihydrotestosterone (DHT), reactivating the androgen receptor despite otherwise effective systemic suppression.
Clinically, one of the longstanding paradoxes has been that intratumoral androgens and androgen receptor activity persist in many patients who are on optimal androgen deprivation therapy, including potent CYP17A1 inhibitors. The newly characterized pathway offers a concrete mechanistic explanation: if cancer cells can shunt cholesterol into DHEA via CYP51A1, they no longer depend on CYP17A1, so drugs designed to shut down CYP17A1 leave this bypass route untouched. That makes CYP51A1‑mediated steroidogenesis a plausible driver of castration resistance and progression under “maximal” hormonal therapy.
In preclinical models, the investigators demonstrated that only CYP51A1, among dozens of tested cytochrome P450 enzymes, could convert the relevant oxysterol into DHEA. Knocking out CYP51A1 in androgen‑driven prostate cancer cells abolished their ability to make testosterone and DHT from cholesterol, which in turn slowed tumor growth and dampened androgen‑responsive gene expression in castrated animal models. Pharmacologic experiments showed another critical point: selective CYP17A1 inhibitors did not block androgen production along this new route, whereas broader P450 inhibition that includes CYP51A1 could shut it down. Together, these data establish CYP51A1 as the gateway of a genuine, functionally important bypass pathway.

This finding has immediate conceptual implications for drug development. If resistance is partly maintained by a CYP51A1‑dependent androgen supply, then truly effective hormonal therapy for advanced prostate cancer may need to co‑target both the classical CYP17A1 axis and this newly defined CYP51A1 route. Ketoconazole’s historical, modest activity in castration‑resistant disease, despite being crude and toxic, now looks like an early, non‑selective glimpse of what purpose‑built CYP51A1 inhibition might achieve when combined with modern agents. The logical next step is to design selective CYP51A1 inhibitors, or rational combinations, that can be tolerated chronically and tested in patients whose tumors show biochemical evidence of this pathway.

Source.